Communicating the benefit/risk ratio to the general public

Vaxzevria’s B/R was re-assessed several times, either because new data became available or because of safety issues arising from the market. With each assessment, the regulatory authorities concluded with their opinion regarding the vaccine’s B/R. This opinion was then incorporated into the national vaccination programs.